This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: uniQure (QURE), Biohaven Ltd. (BHVN)

Tipranks - Tipranks - Fri Jun 19, 6:38AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on uniQure (QURE), Biohaven Ltd. (BHVN) and Align Tech (ALGN) with bullish sentiments.

Claim 55% Off TipRanks

uniQure (QURE)

In a report released yesterday, Joseph Schwartz from Leerink Partners reiterated a Buy rating on uniQure, with a price target of $70.00. The company’s shares closed last Wednesday at $48.16.

According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 30.1% and a 53.3% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Atrium Therapeutics, Inc., Crinetics Pharmaceuticals, and Maze Therapeutics, Inc. ;'>

Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $54.56, implying a 25.3% upside from current levels. In a report released yesterday, Cantor Fitzgerald also upgraded the stock to Buy.

See Insiders’ Hot Stocks on TipRanks >>

Biohaven Ltd. (BHVN)

Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Biohaven Ltd. today and set a price target of $21.00. The company’s shares closed last Wednesday at $13.62.

According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of 8.9% and a 46.4% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as MapLight Therapeutics, Inc., ACADIA Pharmaceuticals, and Definium Therapeutics. ;'>

Biohaven Ltd. has an analyst consensus of Moderate Buy, with a price target consensus of $18.64.

Align Tech (ALGN)

Piper Sandler analyst Jason Bednar reiterated a Buy rating on Align Tech today and set a price target of $235.00. The company’s shares closed last Wednesday at $173.53, close to its 52-week low of $157.57.

According to TipRanks.com, Bednar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.3% and a 39.3% success rate. Bednar covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Solventum Corporation, and Merit Medical Systems. ;'>

Align Tech has an analyst consensus of Moderate Buy, with a price target consensus of $208.00, representing a 16.0% upside. In a report released yesterday, TipRanks – DeepSeek also upgraded the stock to Buy with a $197.00 price target.

Read More on QURE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).